Detailed Sub-study Analysis of the SECRAB Trial: Quality of Life, Cosmesis and Chemotherapy Dose Intensity

• Published in: Clinical oncology (Royal College of Radiologists (Great Britain)) 2023-06, Vol.35 (6), p.397-407
• Main Authors: Fernando, I.N., Lax, S., Bowden, S.J., Ahmed, I., Steven, J.H., Churn, M., Brunt, A.M., Agrawal, R.K., Canney, P., Stevens, A., Rea, D.W.
• Format: Article
• Language: English
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - surgery; Chemoradiotherapy, Adjuvant; chemotherapy; Chemotherapy, Adjuvant - methods; clinical trial; cosmesis; Cyclophosphamide - therapeutic use; dose intensity; Female; Fluorouracil; Humans; Methotrexate - therapeutic use; Original; Prospective Studies; Quality of Life; radiotherapy; secondary outcomes; SECRAB
• ISSN: 0936-6555; 1433-2981
• DOI: 10.1016/j.clon.2023.03.007

SECRAB was a prospective, open-label, multicentre, randomised phase III trial comparing synchronous to sequential chemoradiotherapy (CRT). Conducted in 48 UK centres, it recruited 2297 patients (1150 synchronous and 1146 sequential) between 2 July 1998 and 25 March 2004. SECRAB reported a positive therapeutic benefit of using adjuvant synchronous CRT in the management of breast cancer; 10-year local recurrence rates reduced from 7.1% to 4.6% (P = 0.012). The greatest benefit was seen in patients treated with anthracycline–cyclophosphamide, methotrexate, 5-fluorouracil (CMF) rather than CMF. The aim of its sub-studies reported here was to assess whether quality of life (QoL), cosmesis or chemotherapy dose intensity differed between the two CRT regimens. The QoL sub-study used EORTC QLQ-C30, EORTC QLQ-BR23 and the Women's Health Questionnaire. Cosmesis was assessed: (i) by the treating clinician, (ii) by a validated independent consensus scoring method and (iii) from the patients' perspective by analysing four cosmesis-related QoL questions within the QLQ-BR23. Chemotherapy doses were captured from pharmacy records. The sub-studies were not formally powered; rather, the aim was that at least 300 patients (150 in each arm) were recruited and differences in QoL, cosmesis and dose intensity of chemotherapy assessed. The analysis, therefore, is exploratory in nature. No differences were observed in the change from baseline in QoL between the two arms assessed up to 2 years post-surgery (Global Health Status: –0.05; 95% confidence interval –2.16, 2.06; P = 0.963). No differences in cosmesis were observed (via independent and patient assessment) up to 5 years post-surgery. The percentage of patients receiving the optimal course-delivered dose intensity (≥85%) was not significantly different between the arms (synchronous 88% versus sequential 90%; P = 0.503). Synchronous CRT is tolerable, deliverable and significantly more effective than sequential, with no serious disadvantages identified when assessing 2-year QoL or 5-year cosmetic differences. •SECRAB assessed synchronous or sequential CRT in breast cancer.•Synchronous CRT showed positive therapeutic benefit; sub-studies are reported here.•Quality of life was similar in patients receiving synchronous or sequential CRT.•Cosmesis was similar in patients receiving synchronous or sequential CRT.•Chemotherapy dose intensity was comparable between the two CRT regimens.